abil
smallinterf
rna
sirna
silenc
specif
target
gene
offer
tool
studi
gene
function
also
repres
novel
approach
treatment
variou
human
diseas
clinic
use
howev
sever
hamper
lack
deliveri
molecul
target
cell
popul
vivo
due
instabl
ineffici
cell
entri
poor
pharmacokinet
profil
variou
deliveri
vector
includ
liposom
polym
nanoparticl
thu
develop
order
circumv
problem
review
present
comprehens
overview
barrier
recent
progress
local
system
deliveri
therapeut
sirna
use
lipid
vector
differ
strategi
formul
sirnaload
lipid
particl
well
gener
concern
safe
use
vivo
also
discuss
final
current
advanc
target
deliveri
sirna
impact
field
rna
interfer
rnai
base
therapi
present
discoveri
rna
interfer
rnai
fire
mello
late
open
entir
new
field
gene
therapi
previous
gene
therapi
mainli
concentr
concept
introduc
new
gene
cell
correct
genet
defect
mire
variou
technic
issu
lack
efficaci
vex
issu
unwelcom
integrationinduc
chang
host
gene
express
rare
instanc
result
cancer
rnai
form
dsrna
call
shortinterf
rna
sirna
provid
fresh
approach
field
via
abil
turn
singl
target
gene
without
genom
integr
thu
avoid
issu
gene
therapi
offer
promis
outcom
area
pioneer
antisens
rna
year
earlier
establish
introduct
sirna
cell
effici
trigger
natur
occur
gene
silenc
mechan
therebi
permit
use
pharmacolog
agent
dsrna
gener
bp
length
work
bind
mrna
target
gene
via
basepair
interact
therebi
ensur
high
degre
target
specif
subsequ
inhibit
gene
express
destruct
target
mrna
whole
process
extrem
effici
due
fact
sirna
destroy
process
use
major
advantag
antisens
technolog
date
numer
sirna
target
identifi
variou
diseas
model
rang
cancer
infecti
neurodegen
diseas
major
issu
confront
therapeut
use
sirna
howev
ineffici
deliv
molecul
target
cell
popul
vivo
due
instabl
molecul
well
poor
cellular
uptak
pharmacokinet
profil
vivo
much
effort
therefor
devot
develop
suitabl
vivo
sirna
deliveri
system
among
lipid
deliveri
vector
show
great
promis
due
favor
characterist
biocompat
eas
largescal
product
use
gene
therapi
current
investig
sever
clinic
trial
treatment
diseas
cancer
cystic
fibrosi
review
present
overview
barrier
recent
progress
local
system
sirna
deliveri
use
lipid
vector
differ
strategi
formul
sirnaload
lipid
particl
well
gener
concern
safe
use
vivo
also
discuss
detail
final
current
advanc
target
deliveri
sirna
present
local
deliveri
sirna
ideal
diseas
target
site
easili
access
skin
mucos
surfac
advantag
circumv
potenti
side
effect
result
system
administr
avoid
firstpass
hepat
clearanc
make
like
therapeut
concentr
reach
target
site
date
local
applic
sirna
wide
investig
diseas
agerel
macular
degener
amd
respiratori
viru
infect
local
deliveri
may
also
appli
cancer
tumor
easili
access
success
intratumor
deliveri
sirna
report
gener
local
deliveri
categoris
five
main
group
mucos
intranas
intratrach
intravagin
intrarect
intraocular
transderm
intrathec
intratumor
exampl
applic
summaris
tabl
one
surpris
find
alway
necessari
actual
use
deliveri
vector
local
deliveri
although
highli
depend
target
site
exampl
sever
phase
ii
clinic
trial
investig
intraocular
deliveri
nake
sirna
treatment
wet
amd
review
target
gene
vascular
endotheli
growth
factor
vegf
overexpress
well
establish
basi
diseas
result
posit
must
note
sirna
recent
shown
work
unexpect
way
rather
specif
silenc
vegf
gene
nake
sirna
function
reduc
vegf
express
via
activ
innat
immun
respons
bind
tolllik
receptor
effect
requir
cellular
uptak
howev
other
shown
local
deliveri
nake
sirna
work
bitko
colleagu
demonstr
specif
gene
silenc
use
nake
sirna
intranas
deliveri
absenc
interferon
respons
interestingli
compar
deliveri
sirna
without
transfect
reagent
case
transit
tko
tm
note
margin
enhanc
knockdown
respiratori
syncyti
viru
rsv
target
gene
lipid
agent
use
note
mechan
cell
take
sirna
molecul
remain
unknown
contrast
studi
zhang
colleagu
report
ineffici
uptak
nake
sirna
vagin
tissu
intravagin
administr
deliveri
effici
dramat
improv
use
lipofectamin
tm
like
due
rapid
degrad
ineffici
mucos
uptak
nake
sirna
vagin
caviti
differ
studi
describ
like
reflect
differ
physic
biolog
environ
differ
applic
site
numer
studi
also
report
benefit
use
cation
lipid
vector
local
deliveri
sirna
treatment
diseas
respiratori
viru
infect
cancer
inflamm
disord
see
tabl
cation
lipid
system
facilit
sirna
deliveri
due
effici
interact
cell
membran
nucleic
acid
concern
regard
safeti
use
vivo
rais
recent
studi
perform
wu
colleagu
studi
shown
inflamm
occur
vagin
tissu
follow
intravagin
administr
oligofectamin
tm
cation
lipid
transfect
reagent
though
observ
like
due
high
concentr
oligofectamin
tm
use
previous
establish
cation
lipid
may
provok
inflamm
respons
neutral
one
level
nonspecif
effect
depend
dosag
type
lipid
use
well
nitrogenphosph
np
ratio
employ
review
despit
favor
biocompat
profil
neutral
lipid
use
gene
deliveri
gener
limit
lack
interact
anion
nucleic
acid
overcom
issu
soutschek
et
al
conjug
cholesterol
directli
sensestrand
sirna
duplex
strategi
shown
significantli
enhanc
deliveri
vivo
preserv
antisens
activ
molecul
use
cholesterolconjug
sirna
target
herp
simplex
viru
hsv
wu
colleagu
report
effici
silenc
hsvrelat
gene
intravagin
administr
without
provok
inflamm
interferon
respons
administr
site
high
dose
cholesterolsirna
nmol
requir
studi
howev
like
limit
therapeut
use
thu
recent
develop
biocompat
cation
lipid
cholesterolbas
polyamin
lipid
n
deriv
may
play
signific
role
futur
applic
sirna
treatment
local
diseas
system
administr
feasibl
mean
deliv
sirna
molecul
treatment
diseas
cancer
metabol
disord
target
site
easili
access
achiev
via
intraven
intraperiton
subcutan
inject
intraven
administr
wide
investig
deliveri
rout
date
owe
simplic
procedur
well
fast
distribut
particl
variou
tissu
site
intraperiton
rout
administr
also
studi
treatment
diseas
sepsi
ebola
viru
infect
cancer
although
clinic
accept
repeat
administr
may
limit
due
risk
infect
cathet
implant
although
report
demonstr
success
deliveri
sirna
variou
tissu
site
intraven
inject
nake
sirna
use
suitabl
deliveri
system
significantli
improv
efficaci
vivo
thu
area
intens
research
recent
year
despit
success
cation
lipid
vector
deliv
sirna
local
applic
format
aggreg
result
undesir
interact
vector
anion
serum
protein
gener
preclud
use
system
deliveri
aggreg
also
often
accumul
firstpass
organ
lung
liver
sever
hinder
deliveri
tissu
strategi
therefor
develop
circumv
problem
includ
use
polyethylen
glycol
peg
shield
posit
charg
particl
surfac
well
use
neutral
lipid
deliv
sirna
molecul
system
due
limit
electrostat
interact
vector
anion
sirna
howev
formul
system
often
requir
sophist
techniqu
exampl
formul
procedur
summar
fig
tabl
ii
factor
complex
procedur
stabil
final
product
well
result
particl
size
taken
consider
choos
formul
method
recent
develop
hfdm
method
exampl
show
promis
formul
sirnaload
pegyl
lipid
particl
due
simplic
well
superior
stabil
final
product
date
formul
procedur
wide
employ
prepar
sirnaload
particl
treatment
dyslipidemia
cancer
viral
infect
see
tabl
iii
iv
discuss
recent
advanc
impact
field
rnai
therapi
direct
conjug
cholesterol
sirna
molecul
first
demonstr
soutschek
colleagu
improv
deliveri
effici
sirna
target
apoliproprotein
b
apob
liver
jejunum
intraven
inject
deliveri
strategi
also
recent
adapt
deliv
sirna
subcutan
treatment
diabet
nephropathi
mice
good
success
studi
howev
requir
use
high
dose
cholesterolconjug
sirna
mgkg
significantli
limit
therapeut
applic
human
due
cost
effort
improv
deliveri
effici
system
wolfrum
colleagu
show
interact
conjug
lipoprotein
particl
bloodstream
crucial
cellular
uptak
preassembl
conjug
hdl
thu
demonstr
five
time
effici
silenc
apob
express
mice
compar
equal
amount
cholesterolsirna
conjug
along
abil
particl
accumul
wide
rang
tissu
intraven
administr
dramat
improv
therapeut
potenti
cholesterolconjug
sirna
apart
chemic
conjug
anoth
strategi
deliv
sirna
system
entrap
sirna
molecul
neutral
lipid
particl
neutral
vector
gener
deem
favor
cation
one
biocompat
also
superior
pharmacokinet
profil
lack
interact
neutral
lipid
anion
polynucleotid
howev
usual
result
low
entrap
effici
formul
process
circumv
problem
sempl
colleagu
util
phsensit
ioniz
aminolipid
dodap
pk
entrap
antisens
oligonucleotid
use
ethanol
dialysi
techniqu
lipid
exhibit
neutral
charg
physiolog
ph
cation
natur
acid
ph
provid
mean
effici
interact
nucleic
acid
entrap
effici
report
use
sirna
deliveri
also
recent
demonstr
herringson
colleagu
although
small
amount
cation
lipid
dotap
report
essenti
order
achiev
high
entrap
effici
studi
altern
landen
colleagu
develop
method
formul
dioleoylphosphatidylcholin
dopc
encapsul
sirna
liposom
involv
dissolv
dopc
sirna
tertbutanol
presenc
tween
tm
follow
lyophil
rehydr
although
mechan
lipid
interact
sirna
unclear
method
prepar
report
result
encapsul
effici
use
deliveri
system
reduct
tumor
growth
report
intraven
intraperiton
administr
sirna
target
mice
bear
intraperiton
implant
ovarian
tumor
therapeut
potenti
treatment
malign
diseas
remain
investig
pegyl
cation
lipid
particl
wide
employ
deliv
sirna
system
due
superior
pharmacokinet
profil
includ
enhanc
circulatori
halflif
compar
nonpegyl
counterpart
presenc
cation
lipid
system
also
ensur
effici
interact
lipid
anion
nucleic
acid
therebi
result
higher
entrap
effici
formul
made
use
neutral
lipid
vs
see
tabl
ii
despit
presenc
peg
formul
also
shown
reduc
gene
transfer
effici
target
cell
like
contribut
peg
interfer
cellular
uptak
releas
nucleotid
endosom
compart
strategi
therefor
develop
overcom
problem
summar
fig
strategi
incorpor
exist
pegyl
lipid
system
optim
deliveri
effici
discuss
two
success
pegyl
cation
lipid
system
date
system
deliveri
sirna
stabl
nucleic
acidlipid
particl
snalp
b
lipidprotaminedna
hyaluron
acid
lpdlph
nanoparticl
jeff
et
al
develop
novel
spontan
vesicl
format
method
prepar
nucleotideentrap
cation
pegyl
liposom
formul
method
lipid
solut
first
prepar
vv
ethanol
mix
aqueou
solut
dna
control
manner
use
tconnector
mix
result
ethanol
concentr
drop
valu
requir
support
lipid
solubl
led
precipit
solubil
lipid
spontan
liposom
form
entrap
dna
insid
liposom
stabil
dilut
final
ethanol
remov
dialysi
control
stepwis
mix
process
employ
method
ensur
reproduc
particl
format
procedur
subsequ
adapt
morrissey
colleagu
encapsul
sirna
result
particl
usual
term
snalp
stabl
nucleic
acidlipid
particl
use
snalp
system
morrissey
colleagu
demonstr
decreas
serum
hepat
b
viru
hbv
dna
level
mice
follow
intraven
inject
snalpcontain
sirna
target
hbv
success
deliveri
system
led
first
system
sirna
deliveri
studi
nonhuman
primat
use
dose
low
mgkg
zimmermann
colleagu
show
decreas
apob
express
liver
dramat
reduct
serum
apob
protein
cholesterol
lowdens
lipoprotein
level
cynomolgu
monkey
silenc
potenc
report
greater
achiev
cholesterolconjug
siapob
import
note
apob
hepatocyteexpress
gene
silenc
gene
indic
effect
deliveri
snalp
hepatocyt
instead
kupffer
cell
special
macrophag
locat
liver
form
part
reticuloendotheli
system
re
signific
suggest
pegyl
particl
target
tissu
outsid
re
thu
indic
potenti
applic
clinic
set
inde
judg
et
al
recent
demonstr
success
deliveri
sirna
direct
pololik
kinas
solid
tumor
mice
use
snalp
result
reduct
subcutan
tumor
size
addit
intraperiton
administ
snalp
contain
sirna
target
polymeras
l
gene
ebola
viru
ebov
also
shown
protect
guinea
pig
viremia
death
follow
ebov
challeng
overal
develop
snalp
deliveri
system
show
great
promis
system
applic
rnai
therapi
recent
studi
design
improv
snalp
concentr
develop
novel
chemic
method
allow
rapid
synthesi
larg
librari
lipidlik
deliveri
molecul
term
lipidoid
test
efficaci
sirna
deliveri
snalp
formul
contain
promis
lipidoid
molecul
recent
demonstr
akinc
colleagu
achiev
reduct
apob
fvii
factor
express
hepatocyt
nonhuman
primat
mice
silenc
still
observ
day
modifi
system
report
reduc
total
mass
deliveri
materi
rel
sirna
compar
origin
snalp
formul
result
reduc
toxic
demonstr
decreas
elev
alt
ast
enzym
administr
featur
favor
clinic
applic
selfassembl
lpd
nanoparticl
first
develop
huang
laboratori
deliv
dna
plasmid
vaccin
deliveri
system
subsequ
modifi
deliv
sirna
sirna
dna
mixtur
first
condens
cation
polypeptid
protamin
condens
core
wrap
within
cation
lipid
membran
facilit
cellular
uptak
peglipid
moieti
without
target
ligand
subsequ
postinsert
onto
particl
surfac
provid
surfac
protect
target
specif
inclus
calfthymu
dna
formul
overcom
common
issu
incomplet
condens
sirna
lipid
vector
therebi
provid
enhanc
protect
sirna
nucleas
degrad
result
particl
demonstr
achiev
significantli
higher
level
tumor
local
follow
system
administr
compar
snalp
system
highlight
potenti
use
cancer
therapi
circulatori
halflif
particl
found
h
longer
report
snalp
system
h
differ
could
howev
partial
explain
differ
dose
administr
detect
techniqu
use
studi
use
lpd
particl
li
colleagu
show
reduct
subcutan
tumor
growth
reduct
lung
metastasi
two
three
dose
lpd
particl
contain
sirna
target
vegf
andor
cmyc
dose
mgkg
import
note
dose
regimen
significantli
lower
use
judg
colleagu
treatment
subcutan
tumor
use
snalp
system
see
tabl
iii
despit
success
dosedepend
elev
variou
inflammatori
immun
cytokin
includ
report
system
administr
lpd
nanoparticl
nonspecif
immunotox
later
found
overcom
replac
calfthymu
dna
hyaluron
acid
high
mw
anion
polysaccharid
similar
calfthymu
dna
hyaluron
acid
effici
facilit
condens
sirna
presenc
protamin
result
much
lower
immunotox
due
lack
immunostimulatori
cpg
motif
result
formul
term
lph
lipidprotaminehyaluron
acid
nanoparticl
use
deliveri
system
chono
colleagu
show
reduct
luciferas
activ
luciferas
tumor
lung
mice
follow
singl
intraven
inject
sirna
target
luciferas
mgkg
due
signific
decreas
nonspecif
inflammatori
side
effect
compar
lpd
nanoparticl
lph
system
present
clinic
accept
sirna
deliveri
vector
one
major
issu
confront
clinic
use
lipid
system
sirna
deliveri
toxic
sideeffect
profil
toxic
lipid
deliveri
system
gener
depend
type
lipid
lipidsirna
ratio
use
exampl
formul
contain
dope
typic
display
poorer
toxic
profil
concern
also
rais
nonspecif
activ
inflammatori
cytokin
interferon
respons
lipid
vector
colleagu
exampl
report
potent
induct
type
type
ii
interferon
respons
well
activ
stat
follow
intraven
administr
sirnacontain
dotap
lipoplex
judg
colleagu
also
report
similar
result
dodmacontain
sirnaload
snalp
immunostimulatori
effect
like
result
introduct
cell
sirna
expos
sirna
tolllik
receptor
within
endosom
cell
shown
effect
somewhat
sequencedepend
sirna
contain
highli
immunostimulatori
compar
sirna
deliv
use
lipid
vector
sever
studi
also
indic
possibl
involv
sequenc
motif
factor
phenomenon
apart
chemic
modif
sirna
molecul
substitut
methyl
uridin
guanosin
residu
optim
deliveri
system
also
play
role
reduc
nonspecif
effect
hulieskovan
colleagu
exampl
show
contrast
lipid
vector
system
deliveri
highli
immunostimulatori
sirna
use
cyclodextran
induc
interferon
respons
specul
endosom
buffer
capac
cyclodextran
deliveri
system
contribut
observ
shown
sioud
et
al
endolysosom
acidif
process
crucial
sirnamedi
immunostimulatori
phenomenon
remain
investig
whether
incorpor
polym
contain
high
level
histidin
pk
residu
secondarytertiari
amin
moieti
liposom
formul
abl
reduc
effect
due
proton
spong
mechan
review
effort
must
made
minim
disturb
physiolog
subject
receiv
sirna
treatment
import
note
nonspecif
immunostimulatori
respons
may
therapeut
benefit
certain
clinic
scenario
recent
studi
report
poeck
colleagu
clearli
indic
potenti
ad
benefit
bifunct
sirna
melanoma
cancer
mous
model
activ
innat
immun
system
demonstr
synergist
promot
tumor
cell
apoptosi
immunostimulatori
sirna
target
administ
intraven
use
linear
polyethylenimin
deliveri
vector
whether
observ
translat
cancer
model
infecti
diseas
remain
investig
attach
target
moieti
surfac
deliveri
vector
shown
enhanc
deliveri
sirna
target
cell
popul
vivo
thu
improv
therapeut
outcom
must
note
howev
presenc
target
ligand
gener
affect
overal
pharmacokinet
profil
biodistribut
deliveri
vector
one
biodistribut
studi
perform
use
positron
emiss
tomographi
bioluminesc
imag
exampl
clearli
reveal
lack
correl
presenc
transferringtarget
ligand
level
tumor
local
stealth
sirnacontain
nanoparticl
instead
improv
therapeut
outcom
observ
studi
attribut
enhanc
cellular
uptak
via
receptormedi
endocytosi
target
ligand
present
formul
ligandtarget
strategi
thu
benefici
system
deliveri
pegyl
particl
presenc
peg
interfer
cell
entri
deliveri
sirna
cell
popul
passiv
take
sirnacontain
particl
readili
see
tabl
v
target
ligand
investig
date
gener
categor
three
main
group
glycosyl
molecul
peptid
protein
includ
antibodi
review
choic
ligand
depend
target
cell
popul
transferrin
tf
arginineglycineaspart
acid
rgd
moieti
wide
appli
cancer
therapi
receptor
ligand
highli
upregul
variou
malign
tissu
cell
hulieskovan
colleagu
exampl
demonstr
signific
inhibit
tumor
growth
murin
model
metastat
ewe
sarcoma
use
sirnaentrap
tftarget
stealth
cyclodextran
nanoparticl
contrast
sirna
entrap
correspond
nontarget
nanoparticl
show
antitumor
effect
due
lack
cellular
uptak
deliveri
system
subsequ
form
basi
first
clinic
trial
system
target
deliveri
sirna
treatment
solid
tumor
commenc
apart
transferrin
attach
folic
acid
rgd
moieti
sirna
deliveri
system
also
report
treatment
cancer
see
tabl
v
howev
target
moieti
easi
prepar
handl
also
bind
nontarget
tissuescel
compet
bind
nativ
molecul
bodi
contrast
antibodymedi
cell
target
specif
although
applic
cancer
therapi
limit
due
heterogen
natur
cancer
cell
well
lack
identif
suitabl
antibodi
differ
cancer
type
nevertheless
success
target
leukocyt
human
immunodefici
viru
hiv
infect
cell
report
use
antibodi
target
strategi
sirna
deliveri
technolog
rna
interfer
show
great
promis
less
decad
applic
progress
bench
clinic
trial
system
applic
sirna
molecul
howev
much
challeng
nevertheless
deliveri
technolog
snalp
lph
system
emerg
promis
candid
system
display
favor
pharmacokinet
profil
result
accumul
sirna
target
tissu
follow
administr
despit
success
effort
futur
need
concentr
develop
effect
safer
deliveri
system
better
specif
target
site
effect
target
novel
site
microtumor
central
nervou
system
one
next
challeng
moreov
exclus
deliveri
sirna
specif
tissu
site
possibl
follow
system
administr
import
ensur
specif
sirna
gene
target
well
complet
understand
function
diseas
normal
tissu
envisag
increas
develop
suitabl
formul
reliabl
prepar
procedur
rnaibas
therapi
play
signific
role
treatment
variou
human
diseas
near
futur
